Whither accelerated approval?
Amid the hubbub over new Medicare coverage restrictions for Alzheimer’s treatments, a key issue may not be fully appreciated: There is now bona fide pushback against accelerated approval, a controversial strategy used by regulators and companies to get new drugs to market faster than usual.
On its face, this suggests potentially wider — and sobering — implications for the pharmaceutical industry and patients, because they may one day have to wait longer for new medicines to get out the proverbial door.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
